British cost watchdog recommends Thrombogenics eye drug
BRUSSELS (Reuters) - Belgian biotech group Thrombogenics said on Monday that its main drug Jetrea, which treats eye disease, was recommended for reimbursement by British healthcare cost watchdog NICE.
Jetrea, which treats vitreomacular adhesion, an ageing-related vision problem that can lead to blindness, was recommended for full reimbursement, also for those patients with early stage symptoms, Thrombogenics said.
(Reporting by Robert-Jan Bartunek)
- Putin dissolves state news agency, tightens grip on Russia media
- North Korea says Kim's powerful uncle dismissed for 'criminal acts'
- Thai PM calls snap election, protesters want power now |
- Record cold, ice grip U.S.; more snow to blanket East
- Protesters fell Lenin statue, tell Ukraine's president 'you're next'
Protesters respond to calls to defend their demonstration from possible police intervention. Slideshow